

Pie Chart Graphic – Alternate Text

Section labels/percentages

Metastatic NSCLC

- RIT1 0.2%
- NRTK fusion 0.1%⁴
- NRG1 fusion 0.3%³
- FGFR1 or FGFR2 0.7%
- HRAS 1.2%
- NRAS 1.2%
- MAP2K1 0.7%
- ERBB2 amplification 2.7%
- MET amplification 2.5%
- RET fusion 2.3% Other 25%²
- ROS1 fusion 1.9%
- ALK fusion 4.4%
- MET splice 3.0%
- ERBB2 3.8%
 - Exon 20 insertions 48%⁵
- NF1 truncation 1.9%
- BRAF 5.5%

EGFR 30.3%

- Exon 20 ins 9%¹
- Complex 11%¹
- Classical+ T790M 11%¹
- Atypical 13%¹
- L858R 23%¹
- Ex19del 33%¹

KRAS 29.9%

- G12C 35%²
- Other 25%²
- G12V 17%²
- G12D 14%²
- Q61H 6%²
- G13X 3%²

Citations

Adapted from Skoulidis and Heymach 2019 Nat Rev Can

1 Robichaux et al 2020 WCLC

2 Mack et al 2020 Cancer

3 Jonna et al 2019 Clin Can Res

4 Russo et al 2020 Precis Cancer Med

5 Robichaux et al 2019 Cancer Cell

(MD Anderson Logo)

UNIVERSITY OF TEXAS

MD Anderson

~~Cancer~~ Center

Making Cancer History®

MDA_Logos/MDACC_MasterBrand_Logos/Lores_Screen/

MDACC_RGB_TC_tag_V.png